|
Kauft unter 2$ Forbes Medi-Tech slammed Disappointing trial results lead drug stocks lower By Jenny Spitz, CBS.MarketWatch.com Last Update: 11:30 AM ET April 6, 2004 SAN FRANCISCO (CBS.MW) -- Drug stocks headed lower Tuesday after disappointing results from a cholesterol-lowering drug study and a general decline in the markets cooled interest in the sector. The Amex Biotechnology Index ($BTK: news, chart, profile) fell 1 percent to 549.76 and the Amex Pharmaceutical Index ($DRG: news, chart, profile) slipped 0.3 percent to 326.86 in morning trading. Forbes Medi-Tech (FMTI: news, chart, profile) plunged $3.70, or 52 percent, to $3.36 following the Canadian biopharmaceutical firm`s release of results from a Phase II clinical trial of its FM-VP4 cholesterol-lowering drug. The study found that the treatment was 11 percent more effective in reducing low-density lipoprotein cholesterol than a placebo, the company said. That result is low compared to how other, similar treatments perform and could affect both the drug`s approval and potential sales. However, Forbes Medi-Tech said it was "encouraged" enough to pursue further development of the drug. |
|
| aus der Diskussion: | -53% -->> da konnte ich nicht wiederstehen.... |
| Autor (Datum des Eintrages): | XTrack (06.04.04 17:40:54) |
| Beitrag: | 6 von 16 (ID:12670923) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |